CTOs on the Move

Octamer

www.octamer.com

 
Octamer is a Belvedere Tiburon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.octamer.com
  • 392 Cecilia Way
    Belvedere Tiburon, CA USA 94920
  • Phone: 415.381.1602

Executives

Name Title Contact Details

Similar Companies

ABIANT INC

ABIANT INC is a Deerfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fisher Wallace Laboratories

The Fisher Wallace Stimulator® is a wearable neurostimulation device cleared by the FDA to treat depression, anxiety and insomnia. During each 20-minute treatment session, the device gently stimulates the brain to produce serotonin and other neurochemi...

Karalex Pharma

Karalex Pharma is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hoodia Products

Hoodia Products is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UroGen

UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel™ drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan™ to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals™, and are continually evaluating new opportunities.